Last updated: February 23, 2026
What is the drug identified by NDC 00781-8016?
NDC 00781-8016 refers to Wilate, a coagulation factor VIII and von Willebrand factor recombinant therapy. It is used for the treatment and prevention of bleeding episodes in patients with von Willebrand disease and hemophilia A.
What are the current market dynamics?
Market size and growth
The global hemophilia treatment market was valued at approximately $11 billion in 2022. The compound annual growth rate (CAGR) from 2023 to 2030 is forecasted at around 6%, driven by increased diagnosis rates, innovative therapies, and expanding reimbursement access.
Key players
Major competitors include:
- Bioverativ (Sanofi) with Elocta and Alprolix
- Pfizer with Xyntha
- Baxalta (before acquisition by Shire, now part of Takeda) with Advate
- Shire/Takeda with various factor products
Wilate's niche is as a recombinant concentrate with long half-life, which positions it in a segment targeting patients needing less frequent dosing.
Market segments
- Hemophilia A (Factor VIII deficiency)
- von Willebrand disease (VWD subtype)
The VWD segment accounts for roughly 20% of sales related to Wilate. The hemophilia segment dominates with approximately 80% of the market.
Regulatory status
Wilate has received approval from the FDA, EMA, and other regulatory bodies for the treatment of adult and pediatric patients. It is marketed mainly in the US, Europe, and select Asian countries.
What are the pricing trends and projections?
Current pricing landscape
In the US, wholesale acquisition costs (WAC) for similar recombinant factor VIII products range from $0.80 to $1.10 per IU. Wilate's price per IU historically was about $0.90, equaling approximately $200,000 annually for a typical adult patient on regular prophylaxis.
Price drivers
- Patents and exclusivity: Wilate's patent protection extends until 2025 in some jurisdictions, affecting pricing power.
- Manufacturing costs: Recombinant plasma-derived therapies entail high costs, justifying premium pricing.
- Reimbursement policies: Insurance coverage and government programs heavily influence actual patient costs.
Future price projections
- Short-term (2023–2025): Prices are expected to stabilize, with slight reductions near patent expiration due to generic/biosimilar competition.
- Mid-term (2026–2030): Prices could decline 10-15% as biosimilar products enter the market, though manufacturers may counter with formulation improvements and extended indications.
Competition from biosimilars
Biosimilars for factor VIII are entering markets in Europe, with prices 20-30% lower than originator products. The US may see delayed biosimilar adoption due to patent litigations and regulatory hurdles.
What are the key factors influencing future market and pricing?
- Patent expirations: Wilate's patent protections expire around 2025, opening potential for biosimilar competition.
- Innovations: Extended half-life products could retain pricing premiums, delaying the impact of biosimilars.
- Regulatory pathways: Fast-track approvals for biosimilars could accelerate price erosion.
- Reimbursement policies: Changes in healthcare coverage could shift pricing strategies.
Summary of projections
| Year |
Estimated Price per IU |
Approximate Annual Cost |
Market Share Change |
| 2023 |
$0.90 |
$200,000 |
Stable |
| 2025 |
$0.85 |
$190,000 |
Slight decline |
| 2027 |
$0.75 |
$165,000 |
Moderate decline |
| 2030 |
$0.70 |
$155,000 |
Continued decline |
Key Takeaways
- Wilate remains a key product within a growing hemophilia market, valued at around $11 billion globally.
- Pricing is aligned with high-cost recombinant therapies, around $0.90 per IU in the US.
- Patent expiration in 2025 drives expectations for biosimilar competition and potential price reductions.
- Market growth is driven by increasing diagnosis rates, treatment access expansion, and innovation in extended half-life products.
- Biosimilar competition may reduce prices by 20-30% within 3-5 years post-patent expiration.
FAQs
-
When does Wilate’s patent expire?
Patents are expected to expire around 2025, depending on jurisdiction-specific extensions.
-
Are biosimilars for Wilate available?
Biosimilars are available in Europe; US approvals are pending or under development.
-
How does Wilate compare in efficacy and safety?
Clinical trials demonstrate comparable efficacy and safety to other recombinant factor VIII products; long-term real-world data support its use.
-
What factors could delay biosimilar entry?
Patent litigations, regulatory delays, and market exclusivity rights can postpone biosimilar availability.
-
What is the impact of new therapies on the Wilate market?
Extended half-life products and gene therapies could reduce demand for current recombinant therapies, influencing prices and market share.
References
[1] MarketWatch. (2022). Hemophilia treatment market size.
[2] IQVIA. (2022). Biosimilar approvals and market entry.
[3] FDA. (2022). Wilate approval and label information.
[4] EvaluatePharma. (2022). Hemophilia market forecast.
[5] EMA. (2022). Biosimilar guidelines and approval status.
